Eibhlin Goggins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eibhlin Goggins has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Brendan Bowman
Division of Nephrology, Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, USA
4 shared publications- Balaji Krishnamachary
Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publications Binu Sharma
Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA
3 shared publicationsJennie Z. Ma
Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA
3 shared publicationsJitendra Gautam
Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia USA
3 shared publications- Mark D. Okusa
Division of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, USA
3 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 12 October 2026
- Published by Wiley in American Journal of Hematology
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy
Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited. Using data from 25 U.S.‐based academic cancer centers, we conducted two target trials examining the association between early receipt of PLEX or early receipt of daratumumab and kidney recovery in patients with newly diagnosed LCCN. Kidney recovery was defined as being alive, not on kidney replacement therapy, and with an improvement of at least one stage of AKI severity, all assessed at 90 days. Secondary outcomes included kidney recovery at 60 and 180 days. Logistic regression with propensity score overlap weights was used to adjust for confounders. Of 549 eligible patients for the PLEX target trial, 158 (28.8%) received PLEX. There was no association between PLEX and kidney recovery at 90 days (OR 1.48, 95% CI: 0.96–2.30). However, in subgroup analyses, PLEX was associated with higher odds of kidney recovery at 90 days among patients with newly diagnosed multiple myeloma compared to those with relapsed disease, as well as higher odds of kidney recovery among those with Stage 3 versus Stage 1 or 2 AKI at the time of LCCN diagnosis. Of 474 patients eligible for the daratumumab target trial, 136 (28.7%) received daratumumab. Daratumumab was not associated with kidney recovery at 90 days (OR 1.46, 95% CI: 0.84–2.55). Thus, in this multicenter cohort study, neither PLEX nor daratumumab was associated with kidney recovery at 90 days.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 329 (2) , F234-F249
Pulsed ultrasound targeted to the spleen mitigates against kidney injury and promotes kidney repair
We developed a safe and effective pulsed ultrasound (pUS) protocol targeting the mouse spleen to block inflammation and reduce AKI of multiple etiologies. By using a model of the AKI to CKD transition, we demonstrated the long-term benefits of pUS. The findings of these studies will be used to advance the human translation of spleen-targeted US as a preventative measure for AKI and CKD.
- 1 August 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 329 (2) , F234-F249
Pulsed ultrasound targeted to the spleen mitigates against kidney injury and promotes kidney repair
We developed a safe and effective pulsed ultrasound (pUS) protocol targeting the mouse spleen to block inflammation and reduce AKI of multiple etiologies. By using a model of the AKI to CKD transition, we demonstrated the long-term benefits of pUS. The findings of these studies will be used to advance the human translation of spleen-targeted US as a preventative measure for AKI and CKD.
- 7 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (12) , 2473-2484
Neuroimmune Control of Inflammation in Acute Kidney Injury and Multiorgan Dysfunction
The nervous and immune systems engage in critical bidirectional communication that influences both physiologic regulation and disease progression. This review discusses the neuroimmune axis and its role in controlling inflammation in AKI and multiorgan dysfunction. Central to this regulation is the inflammatory reflex pathway, which consists of sensory afferent and motor efferent arcs. The cholinergic anti-inflammatory pathway (CAP) suppresses inflammation through vagus nerve activation, norepinephrine release, and α 7 nicotinic acetylcholine receptor signaling in macrophages. Inflammatory mediators activate the afferent vagus nerve, transmitting signals to the brain initiating an anti-inflammatory response. Vagus nerve stimulation and pulsed ultrasound activate the CAP and attenuate inflammation and protect against AKI. Specifically, pulsed ultrasound before kidney ischemia-reperfusion injury reduces inflammation and preserves kidney function in a CAP-dependent manner. Beyond the CAP, other organ systems receive direct vagal innervation, and stimulation of these pathways leads to an anti-inflammatory effect and organ protection. Multiorgan neuroimmune communications, including lung–kidney interactions are discussed, emphasizing their relevance in systemic inflammatory conditions. The role of the inflammatory reflex pathway in sepsis is addressed, emphasizing its potential to modulate the dysregulated immune response contributing to multiorgan failure. Finally, the discussion covers the role of the sympathetic nervous system, particularly renal sympathetic nerve activity, in modulating kidney function and inflammation in AKI. Understanding and targeting these neural circuits may offer novel therapeutic strategies for AKI and related conditions.
- 7 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (12) , 2473-2484
Neuroimmune Control of Inflammation in Acute Kidney Injury and Multiorgan Dysfunction
The nervous and immune systems engage in critical bidirectional communication that influences both physiologic regulation and disease progression. This review discusses the neuroimmune axis and its role in controlling inflammation in AKI and multiorgan dysfunction. Central to this regulation is the inflammatory reflex pathway, which consists of sensory afferent and motor efferent arcs. The cholinergic anti-inflammatory pathway (CAP) suppresses inflammation through vagus nerve activation, norepinephrine release, and α 7 nicotinic acetylcholine receptor signaling in macrophages. Inflammatory mediators activate the afferent vagus nerve, transmitting signals to the brain initiating an anti-inflammatory response. Vagus nerve stimulation and pulsed ultrasound activate the CAP and attenuate inflammation and protect against AKI. Specifically, pulsed ultrasound before kidney ischemia-reperfusion injury reduces inflammation and preserves kidney function in a CAP-dependent manner. Beyond the CAP, other organ systems receive direct vagal innervation, and stimulation of these pathways leads to an anti-inflammatory effect and organ protection. Multiorgan neuroimmune communications, including lung–kidney interactions are discussed, emphasizing their relevance in systemic inflammatory conditions. The role of the inflammatory reflex pathway in sepsis is addressed, emphasizing its potential to modulate the dysregulated immune response contributing to multiorgan failure. Finally, the discussion covers the role of the sympathetic nervous system, particularly renal sympathetic nerve activity, in modulating kidney function and inflammation in AKI. Understanding and targeting these neural circuits may offer novel therapeutic strategies for AKI and related conditions.
- Open Access
- 11 June 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (7) , 1889-1900
Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts
Background: In recent years, there has been an emergence of new antigens discovered in membranous nephropathy (MN). Whether these antigens have impacted the approach to, and management of, MN patients undertaken by nephrologists is still unclear. Methods: We conducted a cross-sectional international survey pertaining to 13 antigens recently discovered in MN. The survey was distributed by the National Kidney Foundation, direct emails, and social media. Result: PLA2R, THSD7A, NELL1, and EXT1/2 testing were readily available while the most common response for other antigen testing was ‘Not Performed’ or ‘Unknown’. All respondents had tested for or treated PLA2R-positive MN. Of 79 respondents, only 12.7% had treated THSD7A, 15.2% for NELL1 and 6.3% for EXT1/2 positive MN. For PLA2R, THSD7A, and NELL1, a majority chose rituximab (75.4, 87.5, and 80.0%, respectively) as initial treatment, and would treat with immunosuppression before completing 6 months of conservative therapy. A majority of respondents would routinely or occasionally omit a kidney biopsy in the setting of positive serum anti-PLA2R antibodies, however, 27.5% would rarely do so. There was no clear consensus across respondents regarding the use of anti-PLA2R serum levels in determining remission. Conclusion: Although many new MN antigens have been discovered, there is limited availability of tests identifying these less common antigens. While the survey suggests potential for utilization of an antigen-tailored approach based on identified differences in screening and treatment practices, there remains a lag in the full adoption of this new information. Further progress in accessibility of antigen testing and research into antigen associations will enable a more individualized approach to the management of MN. Graphical
- 11 June 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (7) , 1889-1900
Open AccessClinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts
Background: In recent years, there has been an emergence of new antigens discovered in membranous nephropathy (MN). Whether these antigens have impacted the approach to, and management of, MN patients undertaken by nephrologists is still unclear. Methods: We conducted a cross-sectional international survey pertaining to 13 antigens recently discovered in MN. The survey was distributed by the National Kidney Foundation, direct emails, and social media. Result: PLA2R, THSD7A, NELL1, and EXT1/2 testing were readily available while the most common response for other antigen testing was ‘Not Performed’ or ‘Unknown’. All respondents had tested for or treated PLA2R-positive MN. Of 79 respondents, only 12.7% had treated THSD7A, 15.2% for NELL1 and 6.3% for EXT1/2 positive MN. For PLA2R, THSD7A, and NELL1, a majority chose rituximab (75.4, 87.5, and 80.0%, respectively) as initial treatment, and would treat with immunosuppression before completing 6 months of conservative therapy. A majority of respondents would routinely or occasionally omit a kidney biopsy in the setting of positive serum anti-PLA2R antibodies, however, 27.5% would rarely do so. There was no clear consensus across respondents regarding the use of anti-PLA2R serum levels in determining remission. Conclusion: Although many new MN antigens have been discovered, there is limited availability of tests identifying these less common antigens. While the survey suggests potential for utilization of an antigen-tailored approach based on identified differences in screening and treatment practices, there remains a lag in the full adoption of this new information. Further progress in accessibility of antigen testing and research into antigen associations will enable a more individualized approach to the management of MN. Graphical
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 328 (6) , F830-F849
Proximal tubule pannexin 1 contributes to mitochondrial dysfunction and cell death during acute kidney injury
Despite the huge medical, economical, and quality of life burden that AKI poses to patients, there are no Food and Drug Administration (FDA)-approved therapeutic or pharmaceutical interventions for AKI. Pannexin 1 (Panx1), which is upregulated in patients with AKI as well as in animals that develop experimental AKI, plays a crucial role in mediating both inflammation and cell death during AKI. Our findings suggest clinical interventions with molecules that inhibit Panx1 channel activity could improve outcomes in AKI patients.
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 328 (6) , F830-F849
Proximal tubule pannexin 1 contributes to mitochondrial dysfunction and cell death during acute kidney injury
Despite the huge medical, economical, and quality of life burden that AKI poses to patients, there are no Food and Drug Administration (FDA)-approved therapeutic or pharmaceutical interventions for AKI. Pannexin 1 (Panx1), which is upregulated in patients with AKI as well as in animals that develop experimental AKI, plays a crucial role in mediating both inflammation and cell death during AKI. Our findings suggest clinical interventions with molecules that inhibit Panx1 channel activity could improve outcomes in AKI patients.
- Open Access
- 18 June 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (8) , 2389-2393
Serum protein electrophoresis patterns and misleading laboratory values in IgG4-RD: what the nephrologist should know
- 18 June 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (8) , 2389-2393
Open AccessSerum protein electrophoresis patterns and misleading laboratory values in IgG4-RD: what the nephrologist should know
- Open Access
- 13 February 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (2) , e1858
Humoral immunity trends in a hemodialysis cohort following SARS‐CoV‐2 mRNA booster: A cohort study
Background and Aims: Patients with end stage kidney disease on hemodialysis are vulnerable to SARS‐CoV‐2 infection. Current guidelines recommend boosters of SARS‐CoV‐2 mRNA‐based vaccines. The long‐term humoral response of hemodialysis patients infected with SARS‐CoV‐2 after receiving a booster of SARS‐CoV‐2 mRNA‐based vaccines has been incompletely characterized. Here, we determined the long‐term humoral response of hemodialysis patients to two and three doses of the Pfizer BioNTech (BNT162b2) mRNA SARS‐CoV‐2 vaccine and investigated the effect of postbooster SARS‐CoV‐2 infection on antibody levels over time. Methods: Samples were collected on a monthly basis and tested for anti‐SARS‐CoV‐2 antibodies against anti‐spike S1 domain. Thirty‐five hemodialysis patients were enrolled in the original study and 27 of these received a booster. Patients were followed up to 6 months after the first two doses and an additional 7 months after the third BNT162b2 dose. Results are presented as the internationally harmonized binding antibody units (BAU/mL). Results: Antibody level significantly increased from prebooster to 2 weeks postbooster, with a median [25th, 75th percentile] rise from 52.72 [28.55, 184.7] to 6216 [3806, 11,730] BAU/mL in the total population. Of patients with a negative or borderline detectable antibody level 6 months after vaccination who received a third dose, 89% developed positive antibody levels 2 weeks postbooster. Postbooster antibody levels declined an average rate of 29% per month in infection‐naïve patients. Antibody levels spiked in patients infected with SARS‐CoV‐2 after receiving a booster but declined rapidly. No patients infected postbooster required hospitalization. Conclusions: A third dose of BNT162b2 restores antibody levels to high levels in dialysis patients but levels decline over time. A third dose did not necessarily prevent infection, but no patients suffered severe infection or required hospitalization. SARS‐CoV‐2 recovered patients appear to have a blunted rise in antibody levels after a third dose. Although patients infected with SARS‐CoV‐2 postbooster had an immediate spike in antibody levels, these declined over time.
- 13 February 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (2) , e1858
Open AccessHumoral immunity trends in a hemodialysis cohort following SARS‐CoV‐2 mRNA booster: A cohort study
Background and Aims: Patients with end stage kidney disease on hemodialysis are vulnerable to SARS‐CoV‐2 infection. Current guidelines recommend boosters of SARS‐CoV‐2 mRNA‐based vaccines. The long‐term humoral response of hemodialysis patients infected with SARS‐CoV‐2 after receiving a booster of SARS‐CoV‐2 mRNA‐based vaccines has been incompletely characterized. Here, we determined the long‐term humoral response of hemodialysis patients to two and three doses of the Pfizer BioNTech (BNT162b2) mRNA SARS‐CoV‐2 vaccine and investigated the effect of postbooster SARS‐CoV‐2 infection on antibody levels over time. Methods: Samples were collected on a monthly basis and tested for anti‐SARS‐CoV‐2 antibodies against anti‐spike S1 domain. Thirty‐five hemodialysis patients were enrolled in the original study and 27 of these received a booster. Patients were followed up to 6 months after the first two doses and an additional 7 months after the third BNT162b2 dose. Results are presented as the internationally harmonized binding antibody units (BAU/mL). Results: Antibody level significantly increased from prebooster to 2 weeks postbooster, with a median [25th, 75th percentile] rise from 52.72 [28.55, 184.7] to 6216 [3806, 11,730] BAU/mL in the total population. Of patients with a negative or borderline detectable antibody level 6 months after vaccination who received a third dose, 89% developed positive antibody levels 2 weeks postbooster. Postbooster antibody levels declined an average rate of 29% per month in infection‐naïve patients. Antibody levels spiked in patients infected with SARS‐CoV‐2 after receiving a booster but declined rapidly. No patients infected postbooster required hospitalization. Conclusions: A third dose of BNT162b2 restores antibody levels to high levels in dialysis patients but levels decline over time. A third dose did not necessarily prevent infection, but no patients suffered severe infection or required hospitalization. SARS‐CoV‐2 recovered patients appear to have a blunted rise in antibody levels after a third dose. Although patients infected with SARS‐CoV‐2 postbooster had an immediate spike in antibody levels, these declined over time.
- Open Access
- 10 January 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (1) , e1040
SARS‐CoV‐2 booster effect and waning immunity in hemodialysis patients: A cohort study
- 10 January 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (1) , e1040
Open AccessSARS‐CoV‐2 booster effect and waning immunity in hemodialysis patients: A cohort study
- Open Access
- 3 October 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (6) , e854
Long‐term humoral immunity decline in hemodialysis patients following severe acute respiratory syndrome coronavirus 2 vaccination: A cohort study
Background and Aims: Dialysis patients are extremely vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection with high rates of hospitalization and mortality rates. In January 2021, the University of Virginia Dialysis Program initiated a program‐wide vaccination campaign to administer the Pfizer BioNTech messenger RNA SARS‐CoV‐2 (BNT162b2) vaccine. The aim of this study was to characterize the long‐term time‐dependent decline in humoral immunity in hemodialysis patients.Methods: A prospective cohort study measuring serial monthly semiquantitative IgG antibody levels to the SARS‐CoV‐2 spike protein receptor binding domain in fully vaccinated in‐center hemodialysis patients. Samples were collected monthly and tested for anti‐SARS‐CoV‐2 antibodies against the anti‐spike S1 domain for 2–6 months post full vaccination. Results were presented as internationally harmonized binding antibody units (BAU/ml). To analyze the change in antibody levels over time, a linear mixed model with random intercept and random slope was used for longitudinal antibody levels. A multivariable model was used to estimate the slope of antibody levels by adjusting for selected patient characteristics. Based on the estimated intercepts and slopes for each subject from the unadjusted model, 10‐month antibody levels were projected.Results: The mean baseline antibody level was 647.59 BAU/ml and 87.88% (29/33) of patients were considered qualitatively positive. Two patients were negative at baseline and an additional two had borderline results. Patient antibody levels declined at an adjusted average rate of 31% per month. At 6 months postvaccination, 40% of patients remaining in the cohort possessed either negative or borderline IgG antibody levels. Projecting future antibody levels suggests that 65% of the cohort will progress to borderline or negative antibody levels at 10 months post full vaccination.Conclusion: The long‐term vaccine response following vaccination with the BNT162b2 in hemodialysis patients was characterized. Our data add to the limited pool of data in this patient population and emphasize the critical need for vaccine boosters.
- 3 October 2022
- Published by Wiley in Health Science Reports
- Vol. 5 (6) , e854
Open AccessLong‐term humoral immunity decline in hemodialysis patients following severe acute respiratory syndrome coronavirus 2 vaccination: A cohort study
Background and Aims: Dialysis patients are extremely vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection with high rates of hospitalization and mortality rates. In January 2021, the University of Virginia Dialysis Program initiated a program‐wide vaccination campaign to administer the Pfizer BioNTech messenger RNA SARS‐CoV‐2 (BNT162b2) vaccine. The aim of this study was to characterize the long‐term time‐dependent decline in humoral immunity in hemodialysis patients.Methods: A prospective cohort study measuring serial monthly semiquantitative IgG antibody levels to the SARS‐CoV‐2 spike protein receptor binding domain in fully vaccinated in‐center hemodialysis patients. Samples were collected monthly and tested for anti‐SARS‐CoV‐2 antibodies against the anti‐spike S1 domain for 2–6 months post full vaccination. Results were presented as internationally harmonized binding antibody units (BAU/ml). To analyze the change in antibody levels over time, a linear mixed model with random intercept and random slope was used for longitudinal antibody levels. A multivariable model was used to estimate the slope of antibody levels by adjusting for selected patient characteristics. Based on the estimated intercepts and slopes for each subject from the unadjusted model, 10‐month antibody levels were projected.Results: The mean baseline antibody level was 647.59 BAU/ml and 87.88% (29/33) of patients were considered qualitatively positive. Two patients were negative at baseline and an additional two had borderline results. Patient antibody levels declined at an adjusted average rate of 31% per month. At 6 months postvaccination, 40% of patients remaining in the cohort possessed either negative or borderline IgG antibody levels. Projecting future antibody levels suggests that 65% of the cohort will progress to borderline or negative antibody levels at 10 months post full vaccination.Conclusion: The long‐term vaccine response following vaccination with the BNT162b2 in hemodialysis patients was characterized. Our data add to the limited pool of data in this patient population and emphasize the critical need for vaccine boosters.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6305
Abstract 6305: Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft
Cancer-induced cachexia is commonly observed in pancreatic cancer. The syndrome induces significant weight loss and leads to morbidity, intolerance to chemotherapy, and mortality. While performing metabolic characterization of the brain and plasma of mice with a cachexia-inducing human pancreatic cancer xenograft we identified significant changes in glutamine metabolism [1] that led us to investigate the effects of altering tumor glutamine metabolism on weight loss. We genetically engineered cachexia inducing Pa04C cells to express shRNA downregulating the glutamine transporter SLC1A5. Tumors derived from Pa04C cells with downregulated SLC1A5 (CSh cells and tumors) exhibited significantly delayed tumor growth compared to empty vector (EV) or wild type (WT) tumors, but escaped growth delay approximately 60 days after inoculation, although SLC1A5 mRNA and protein remained significantly downregulated. Despite tumor growth, mouse weight reduction was significantly attenuated at matched EV and CSh tumor volumes. We next sought to investigate if tumors derived from cells isolated from escaped CSh tumor (TSh cells and tumors) continued to exhibit growth delay and attenuated weight loss when re-inoculated in mice. Quantitative transcriptome profiling by RNA-seq was performed to determine differentially expressed genes in CSh and TSh cells compared to EV cells. Method: EV, CSh or TSh cells were inoculated subcutaneously in male mice. Tumor volumes and weights of tumor bearing mice were recorded until tumors were harvested at ~ 500 mm3 for molecular characterization. RNA was isolated in triplicate from EV, CSh and TSh cells. Transcriptomic analysis was performed by RNA sequencing on a NovaSeq 6000 PE150 platform. All bioinformatics analysis was performed with assistance from the NOVOGENE informatics group. Results: Tumors derived from TSh cells did not exhibit any growth delay unlike tumors derived from CSh cells. SLC1A5 expression remained downregulated in TSh cells and tumors. Despite the loss of growth delay, mice with TSh tumors continued to exhibit attenuated weight loss identifying, suggesting the glutamine transporter as a potential treatment strategy to reduce cachexia. Transcriptomic analysis allowed us to identify the adaptive changes that occurred in CSh tumors that allowed these tumors to escape growth delay despite SLC1A5 downregulation. Transcriptomic differences between TSh and CSh cells were primarily in pathways related to amino acid metabolism, inflammation and the extracellular matrix. These transcriptomic differences allow the identification of novel targets that can be used in combination with glutamine transporter downregulation to arrest the growth of pancreatic cancer cells in vivo. Supported by NIH R35 CA209960 and R01 CA193365. 1) J Cachexia Sarcopenia Muscle. 2020 Dec; 11(6): 1487-1500. Citation Format: Balaji Krishnamachary, Ishwarya Sivakumar, Yelena Mironchik, Raj Kumar Sharma, Santosh Kumar Bharti, Marie-France Penet, Paul Winnard, Eibhlin Goggins, Jiefu Jin, Anirban Maitra, Michael G. Goggins, Zaver M. Bhujwalla. Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6305.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 6305
Open AccessAbstract 6305: Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft
Cancer-induced cachexia is commonly observed in pancreatic cancer. The syndrome induces significant weight loss and leads to morbidity, intolerance to chemotherapy, and mortality. While performing metabolic characterization of the brain and plasma of mice with a cachexia-inducing human pancreatic cancer xenograft we identified significant changes in glutamine metabolism [1] that led us to investigate the effects of altering tumor glutamine metabolism on weight loss. We genetically engineered cachexia inducing Pa04C cells to express shRNA downregulating the glutamine transporter SLC1A5. Tumors derived from Pa04C cells with downregulated SLC1A5 (CSh cells and tumors) exhibited significantly delayed tumor growth compared to empty vector (EV) or wild type (WT) tumors, but escaped growth delay approximately 60 days after inoculation, although SLC1A5 mRNA and protein remained significantly downregulated. Despite tumor growth, mouse weight reduction was significantly attenuated at matched EV and CSh tumor volumes. We next sought to investigate if tumors derived from cells isolated from escaped CSh tumor (TSh cells and tumors) continued to exhibit growth delay and attenuated weight loss when re-inoculated in mice. Quantitative transcriptome profiling by RNA-seq was performed to determine differentially expressed genes in CSh and TSh cells compared to EV cells. Method: EV, CSh or TSh cells were inoculated subcutaneously in male mice. Tumor volumes and weights of tumor bearing mice were recorded until tumors were harvested at ~ 500 mm3 for molecular characterization. RNA was isolated in triplicate from EV, CSh and TSh cells. Transcriptomic analysis was performed by RNA sequencing on a NovaSeq 6000 PE150 platform. All bioinformatics analysis was performed with assistance from the NOVOGENE informatics group. Results: Tumors derived from TSh cells did not exhibit any growth delay unlike tumors derived from CSh cells. SLC1A5 expression remained downregulated in TSh cells and tumors. Despite the loss of growth delay, mice with TSh tumors continued to exhibit attenuated weight loss identifying, suggesting the glutamine transporter as a potential treatment strategy to reduce cachexia. Transcriptomic analysis allowed us to identify the adaptive changes that occurred in CSh tumors that allowed these tumors to escape growth delay despite SLC1A5 downregulation. Transcriptomic differences between TSh and CSh cells were primarily in pathways related to amino acid metabolism, inflammation and the extracellular matrix. These transcriptomic differences allow the identification of novel targets that can be used in combination with glutamine transporter downregulation to arrest the growth of pancreatic cancer cells in vivo. Supported by NIH R35 CA209960 and R01 CA193365. 1) J Cachexia Sarcopenia Muscle. 2020 Dec; 11(6): 1487-1500. Citation Format: Balaji Krishnamachary, Ishwarya Sivakumar, Yelena Mironchik, Raj Kumar Sharma, Santosh Kumar Bharti, Marie-France Penet, Paul Winnard, Eibhlin Goggins, Jiefu Jin, Anirban Maitra, Michael G. Goggins, Zaver M. Bhujwalla. Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6305.